Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Our team can help determine your eligibility and guide you through the entire process
Its extremely short half-life restricts its diffusion capability to other parts of the cells while also enhancing its potency[4]
Our programs are supported by scientific research and designed to address the root causes of obesity rather than provide quick fixes
doi:10.5152 Bakilan, Fulya et al
Obstructive Sleep Apnea (OSA) To treat moderate to severe obstructive sleep apnea in adults with obesity
Its design is based on the sequence of a natural glucose-dependent insulinotropic polypeptide (GIP) and simultaneously activates the glucagon-like peptide-1 (GLP-1) receptor, hence the name "twincretin." The drug first entered clinical research in 2016, with Eli Lilly initiating a Phase I clinical trial to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in obese or overweight subjects with related comorbidities
US$ 22.91
US$ 26.72
US$ 22.20
